A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

NCT07557953 · Recruiting

Last updated 2026-05-28

This study is testing how a medication called cagrilintide affects appetite and food intake in adults who are overweight or have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 120 people Planned (estimated).

Who can join Ages 18–64 · all sexes

Timeline Started 2026-04 · est. completion 2027-04

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07557953 ↗

Description as written by the study sponsor.

The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is the treatment being tested, while placebo looks like the study medicine but does not contain any active medicine. The study will last for about 30 weeks.

Treatments tested

Cagrilintide Drug

Cagrilintide is administered subcutaneously .
Placebo Cagrilintide Drug

Placebo Cagrilintide is administered subcutaneously.

Main thing measured	Relative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07557953 ↗